Op donderdag 19 maart 2026 organiseert het Centrum Infectieziektebestrijding van het RIVM een Vaccinatie Onderzoeksdag. Dit symposium over pneumokokken is bedoeld voor onderzoekers, medisch en public health professionals en beleidsmakers op het terrein van infectieziekten en vaccinatie, en andere geïnteresseerden. 

In Nederland zijn recent het 15-valente vaccin voor kinderen (2024) en het 20-valente vaccin voor ouderen (2025) geïntroduceerd. Aankomende adviezen van de Gezondheidsraad over nieuwe vaccins vragen om een geïntegreerde vaccinatiestrategie voor jong èn oud.

Wat kunt u verwachten?

Tijdens dit symposium geven RIVM-onderzoekers en internationale experts een actueel overzicht van de huidige epidemiologie, ziektelast en diversiteit van pneumokokken in Nederland en onderbouwing voor keuzes van nieuwe conjugaatvaccins en vaccinatie strategieën voor jong en oud.

Keynote speakers

• Prof. dr. Lieke Sanders geeft een inleiding over ontwikkelingen van de pneumokokken epidemiologie onder druk van pneumokokken conjugaatvaccinaties: Dancing with The Red Queen: Veranderende Pneumokokken Epidemiologie en Vaccinatie
• Prof dr. David Glodblatt spreekt over het gebruik van immunologische correlaten van bescherming als basis voor aanpassing van vaccinatie schema’s: Using correlates of protection to adjust vaccine schedules: the UK United Kingdom (United Kingdom) 1+1 experience and implications for predicting the impact for extended valency pneumococcal vaccines
• Prof. dr. Philippe de Wals legt achtergronden uit van de pneumokokken vaccin keuzes in Canada voor kinderen en ouderen: A comprehensive approach to define an optimal immunization strategy against pneumococcal disease
• Prof. dr. Debby Bogaert spreekt over de rol van pneumokokken in samenspel met het respiratoire ecosysteem: Streptococcus pneumonia and the respiratory microbiome

Borrel en receptie

Na afloop van het symposium bent u van harte welkom bij de borrel en receptie ter gelegenheid van het pensioen van Lieke Sanders. U kunt zich apart opgeven voor het symposium, de receptie of alle twee. 

Accreditatie

Er wordt accreditatie aangevraagd bij het ABAN.

Kosten

U kunt gratis aan dit symposium deelnemen.

Programma

Vragen?

Heeft u vragen? Stuur een e-mail naar liesbeth.hoek@rivm.nl.

Elisabeth A.M. Sanders (1959) is paediatrician and professor in paediatric Immunology and Infectious Diseases at the University Medical Centre Utrecht. In 2015 she took up a position as Chief Science Officer at the National Institute for Public Health and the Environment (RIVM). Currently she is senior scientific advisor on immunization strategies. 

She has a long-standing interest in the immune response to vaccines and infectious diseases and initiated various research programmes exploring changes in carriage and immune responses upon immunization, allowing optimization of vaccination schedules. Her research area is focused on immunology, vaccinology and epidemiology of infectious diseases and in particular respiratory infections and human respiratory microbiome development in relation to susceptibility to respiratory infections. She is member of the WHO World Health Organization (World Health Organization )-SAGE working group on pneumococcal vaccines. In addition to her position as CSO Chief Science Officer (Chief Science Officer) at RIVM, she holds her position at the Wilhelmina Children’s Hospital as professor in immunology and infectious diseases.  

Before her position at RIVM, she had a position as head of the clinical department of Immunology and Infectious Diseases as clinician-immunologist at the at the University Hospital for Children in Utrecht (1993-2015). Over the years 2009-2014 she was Director Research and Education of the Children’s University Hospital and board member of two UMCU Universitair Medisch Centrum Utrecht (Universitair Medisch Centrum Utrecht) strategic research themes (1) Child Health and (2) Infection & Immunity. She was member of the Dutch Health Council for the national immunization programme from 2009-2015 and participated in many committees on immunization strategies.  

Infection, Immunity and Inflammation Department 

Great Ormond Street Institute of Child Health, University College London and Great Ormond Street Children’s Hospital NHS neonatale hielprikscreening (neonatale hielprikscreening) Foundation Trust

David Goldblatt is Professor of Vaccinology and Immunology at the Great Ormond Street Institute of Child Health, University College London (UCL) and a Consultant Paediatric Immunologist at the Great Ormond Street Hospital for Children NHS Foundation Trust. He obtained his medical degree from the University of Cape Town, South Africa, a PhD Doctor of Philosophy (Doctor of Philosophy ) in Immunology from the University of London, United Kingdom. He is an Emeritus National Institute for Health Research (NIHR) Senior Investigator.

He has a long-standing interest in the immune response to vaccines and infectious diseases. He has active research programmes exploring immunity to colonisation/ carriage and infection, correlates of protection and assessing alternative vaccines schedules. His laboratory (a WHO World Health Organization (World Health Organization ) Reference Laboratory for Pneumococcal Serology) interests include Streptococcus Pneumoniae, Klebsiella Pneumonia, Group A and B Streptococcus and SARS severe acute respiratory syndrome (severe acute respiratory syndrome)-CoV-2. He is an advisor to the World Health Organisation (WHO) on vaccine schedules and Klebsiella Pneumoniae vaccines and chairs the WHO Technical Advisory Group on Group B Streptococcus vaccines. He serves on subcommittees of the United Kingdom Department of Health Joint Committee on Vaccines and Immunisation (JCVI) and advised the MHRA on COVID Vaccine licensure via membership of the Commission on Human Medicines COVID-19 Vaccines Benefit Risk Expert Working Group. He chairs several Scientific Advisory Boards including the International SAB advising the Malawi-Liverpool-Wellcome Trust Clinical Research Programme in Blantyre. He is currently secretary of the International Society of Pneumonia and Pneumococcal Disease having served as President from 2018 to 2024.

Philippe De Wals gained his Medical Degree and a Doctorate in Public Health in his home country of Belgium, at the Louvain Catholic University. His early academic and professional career combined teaching and epidemiologic research at the Louvain Catholic University School of Public Health in Brussels with the practice of family medicine. In 1990, he moved to Canada and became the Head of the Department of Community Health Sciences at the University of Sherbrooke. In 1997, he was appointed visiting Professor at the School of Public Health at the University of North Carolina in Chapel Hill, USA United States of America (United States of America). In 2002, he became Head of the Department of Social and preventive medicine at Laval University, Quebec City, until 2010. He retired from Laval University in 2019 and remains associate professor at Sherbrooke University and at Laval University, and emeritus professor at the Louvain Catholic University. 

Professor De Wals’ research is centered on the epidemiology of infectious diseases, reproductive abnormalities, and the assessment of health services and public health programs and policies. He is the author of more than 200 articles published in scientific journals and has contributed several chapters to textbooks. Currently, Professor De Wals is a member of research centers at the Quebec University Hospital, the Sherbrooke University Hospital and the Quebec Heart and Lung University Institute. He also serves as medical advisor to the Quebec National Institute of Public Health and the Public Health Agency of Canada. 

In 1990, Professor De Wals was awarded the Jean Van Beneden Prize in recognition of his excellent work in the public health field in Belgium. In 2005, he was elected to the Royal Academy of Medicine of Belgium. He was awarded the price for excellence of the Quebec Community Health Specialists Association in 2007. In 2019, he was an awardee of the Collen-Francqui International Professorship at Antwerp University. In 2023, he received the Dr. Doctor (Doctor ) John Waters Memorial Award in recognition of his outstanding leadership in support of immunization programs and policy in Canada.

Professor Debby Bogaert is a clinician-scientist, specialized in respiratory microbiome research, and focusing on how microbiome composition influences susceptibility, severity, and recovery from respiratory tract infections (RTIs). In 2008, she established one of the first respiratory microbiome research programs worldwide at UMC Universitair Medisch Centrum (Universitair Medisch Centrum) Utrecht, pioneering ecological and clinical studies that helped define the respiratory microbiome as a clinical concept. Her team has developed key metagenomic and bioinformatic pipelines, and with collaborators, executed several prospective early-life, longitudinal cohort and clinical studies. Since 2016 she is also affiliated with the University of Edinburgh, where she expanded microbiome research to low-income settings through collaborations with several African research institutes. Professor Bogaert’s work has advanced understanding of interactions between microbiota, viruses, vaccines, and host immunity, shaping future infection prevention and diagnostic strategies. Alongside her research leadership, she has maintained active clinical practice, contributed to national and international scientific committees, and trained and mentored biomedical postgraduate students and clinician-scientists across Europe, Africa, and the USA United States of America (United States of America).